openPR Logo
Press release

Investigation announced for Long-Term Investors in Instil Bio, Inc. (NASDAQ: TIL) over potential Wrongdoing

02-03-2023 04:54 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Instil Bio, Inc. (NASDAQ: TIL) shares over potential wrongdoing at Instil Bio, Inc.

An investigation on behalf of investors in Instil Bio, Inc. (NASDAQ: TIL) shares over potential wrongdoing at Instil Bio, Inc.

An investigation on behalf of investors in shares of Instil Bio, Inc. (NASDAQ: TIL) was announced over potential breaches of fiduciary duties by certain officers and directors at Instil Bio, Inc.

Investors who purchased shares of Instil Bio, Inc. (NASDAQ: TIL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Instil Bio, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Dallas, TX based Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. On October 31, 2022, before market hours, Instil Bio, Inc.issued a press release entitled "Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing" which announced the pause and that the pause was due to "a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured." Further, the Company announced that "[a]lthough no manufacturing failures have been observed to date in the ongoing Phase 1 trial of ITIL-306, the Company has also voluntarily paused enrollment in this trial as part of its overall manufacturing analysis." The Company also announced that it "intends to provide an update on the manufacturing analysis by early Q1 2023."

Shares of Instil Bio, Inc. (NASDAQ: TIL) declined from $5.26 per share on October 28, 2022, to $2.46 per share on November 1, 2022.

Those who purchased shares of Instil Bio, Inc. (NASDAQ: TIL) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Instil Bio, Inc. (NASDAQ: TIL) over potential Wrongdoing here

News-ID: 2911443 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Instil

VVC Clothing Redefines Premium Streetwear with Motivational Designs That Celebra …
Fashion Brand Combines Remarkable Style with Inspirational Messaging to Empower "1 of 1" Customer Experience VVC Clothing, is a premium streetwear and activewear brand, is revolutionizing the fashion industry by creating designs specifically intended to instil motivation and ambition into every outfit. The brand's unique approach reinforces customers' individual identities while delivering remarkable style that serves as daily inspiration for fashion-conscious men and women. VVC Clothing has built its reputation on the
New Horizons in Global TIL Therapy Market Exploring Future Growth Potential, New …
The Latest research report on the Global TIL Therapy Market 2025 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2032. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Global TIL Therapy Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies,
NSCLC Market Size in the 7MM is expected to grow by 2034 | DelveInsight
DelveInsight's "NSCLC Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Key Takeaways from the NSCLC Market Research Report * The increase in NSCLC Market Size is a direct consequence of the increasing patient population and anticipated launch
TIL Therapy Pipeline Assessment, 2023 Updates | In-depth Insights into the Clini …
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TIL Therapy pipeline landscape globally. "TIL Therapy Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TIL Therapy Therapeutics Market. The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule
Investigation announced for Investors in Instil Bio, Inc. (NASDAQ: TIL) over pos …
An investigation was announced for investors of Instil Bio, Inc. (NASDAQ: TIL) shares over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Instil Bio, Inc. (NASDAQ: TIL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Instil Bio, Inc. regarding its business, its
The Europe Automotive Parts Remanufacturing Market to instil substantial growth …
The Europe automotive parts remanufacturing market is set to be valued over US$ 44 Bn by 2031, according to latest research by Persistence Market Research, a research and consulting firm. The report estimates the market to surge at a steady CAGR of close to 7% though the course of 2021-2031. Government regulatory actions are aimed at gradually increasing resource productivity, potentially leading to environmental pricing. For example, the European Council